Clinical study of Xuefu Zhuyu Capsule in the treatment of acute chest pain after thoracoscopic surgery for early non-small cell lung cancer

Peking University People's Hospital0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•1. Age 18-75 years old (including 18 and 75 years old);
•2. Those who underwent thoracoscopic lobectomy;
•3. Patients with postoperative pathological diagnosis of primary lung cancer or precancerous lesions;
•4. No chest pain before operation, postoperative pain within 3 months, and NRS score = 4;
•5. Those who meet the TCM diagnostic criteria of qi stagnation and blood stasis syndrome;
•6. Voluntarily participate in clinical research and sign informed consent.

•1. Those who meet the diagnostic criteria of primary bronchial lung cancer and have been treated with radiotherapy, chemotherapy, targeted therapy and traditional Chinese medicine in the first 3 months;
•2. Have mental illness, such as unconsciousness and communication disorder;
•3. Patients with serious heart, liver, kidney and cerebrovascular diseases;
•4. Allergic constitution or allergic to the ingredients of Xuefu Zhuyu Capsule and various drugs;
•5. Those who participated in other clinical studies within 3 months before screening;
•6. Pregnant or ready for pregnancy, lactating women;
•7. The researcher considers it inappropriate to participate in this study.

发起方